Breaking Finance News

A statement released earlier today by Needham about Aerie Pharma (NASDAQ:AERI) bumps the target price to $65.00

Having a price of $40.50, Aerie Pharma (NASDAQ:AERI) traded 1.66% higher on the day. With the last close down 24.35% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the same period. Aerie Pharma has recorded a 50-day average of $56.90 and a two hundred day average of $51.75. Volume of trade was down over the average, with 75,598 shares of AERI changing hands under the typical 645,275

Stating a potential upside of 0.60%, Needham upped the price target of Aerie Pharma (NASDAQ:AERI) to $65.00

Performance Chart

Aerie Pharma (NASDAQ:AERI)

With a total market value of $0, Aerie Pharma has with a one year low of $32.05 and a one year high of $66.10 .

A total of 7 analysts have released a report on Aerie Pharma. Three firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $45.71.

Brief Synopsis About Aerie Pharma (NASDAQ:AERI)

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.